Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jan 29:11:15.
doi: 10.1186/s13000-016-0459-5.

Beclin1 and HMGB1 ameliorate the α-synuclein-mediated autophagy inhibition in PC12 cells

Affiliations

Beclin1 and HMGB1 ameliorate the α-synuclein-mediated autophagy inhibition in PC12 cells

Kaihua Wang et al. Diagn Pathol. .

Abstract

Background: Aberrant α-synuclein aggregation due to the deficiency of ubiquitin-proteasome or of autophagy characterizes the parkinson disease (PD). High mobility group box 1 (HMGB1) is a novel stress sensor to mediate the persistent neuro-inflammation and the consequent progressive neurodegeneration, via controlling the cellular autophagy/apoptosis checkpoint during inflammation. Moreover, HMGB1 has been recently indicated to involve in the autophagic degradation of α-synuclein.

Methods: In the current study, we investigated the influence of the overexpressed α-synuclein of wild type (wt) or mutant type (A53T and A30P, mt) on the cytosolic levels of HMGB1 and Beclin1 and on the starvation-induced autophagy in pheochromocytoma PC12 cells. And then we explored the overexpression of HMGB1 or of Beclin1 on the α-synuclein degradation and on the autophagy in the α-synuclein-overexpressed PC12 cells.

Results: It was demonstrated that α-synuclein overexpression inhibited the trans-location of HMGB1 from nucleus to cytosol and reduced the cytosolic level of Beclin1 in PC12 cells, and inhibited the starvation-induced autophagy via downregulating autophagy-associated markers and via reducing the autophagic vesicles in PC12 cells under starvation. On the other side, the intracellular promotion of either HMGB1 or Beclin1 upregulated the α-synuclein degradation and ameliorated the α-synuclein-mediated autophagy reduction in PC12 cells. However, the exogenous HMGB1 treatment exerted no such regulation in PC12 cells.

Conclusion: In summary, our study confirmed the positive regulation by HMGB1 and Beclin1 on the α-synuclein degradation and on the starvation-induced autophagy in PC12 cells, implying both markers as prominent targets to promote the α-synuclein degradation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overexpression of α-synuclein with wild type (wt) or mutant type (mt) reduces cytosolic HMGB1 and Beclin1 in PC12 cells. a and b: mRNA (a) and protein (b) levels of α-synuclein in the PC12 cell overexpressing wt α-synuclein, PC12 (Synwt), in the PC12 cell overexpressing mt (A53T and A30P) α-synuclein, PC12 (Synmt), in the PC12 cell overexpressing Enhanced Green Fluorescence Protein (EGFP), PC12 (Con), or in the blank P12 cells, the protein level of α-synuclein was examined by western blot analysis; c: Western blot analysis of HMGB1 (in cytosol and in nucleus) and Beclin1 (in cytosol) in PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells; d: Relative HMGB1 level to β-actin in cytosol or to Lamin B(LMNB1) in the nucleus of PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells; e: Relative Beclin1 level to β-actin in the cytosol of PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells; Each result was averaged for triple independent experiments. Statistical significance was presented as * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance
Fig. 2
Fig. 2
Levels of autophagy-associated markers and autophagic vesicles induced by starvation in the PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells. a: Western blotting assay of LC3-I, LC3-II, Atg 7 and mTOR in the PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells post an incubation at 37 °C in FBS-free medium for 24 hours; b: Ratio of LC3-II to LC3-I in the starvation-treated cell lines; c: Relative level of Atg 7 and mTOR levels to β-actin in each cell line post the starvation treatment; d and e: Imaging (d) and counting (e) of EGFP-positive autophagic vesicles in the cytosol of starvation-treated PC12, PC12 (Con), PC12 (Synwt) or PC12 (Synmt) cells which were transfected with pCDNA3.1-EGFP-LC3 plasmid for another 24 hours; Data was averaged for triple independent results. * p < 0.05, ** p < 0.01, ns: no significance
Fig. 3
Fig. 3
HMGB1 upregulation inhibits α-synuclein accumulation and ameliorates the α-synuclein-inhibited autophagy in PC12 (Synwt) and PC12 (Synmt) cells. a: Western blot analysis of HMGB1 and α-synuclein in PC12 (Synwt) and PC12 (Synmt) cells, which were transfected with HMGB1-pcDNA3.1(+) or RFP-pcDNA3.1(+) plasmid for 12 or 24 hours; b and c: Ratio of HMGB1 to β-actin in PC12 (Synwt) and PC12 (Synmt) cells with or without HMGB1 promoted; d and e: Ratio of α-synuclein to β-actin in PC12 (Synwt) and PC12 (Synmt) cells, with or without HMGB1 promoted; f and g: Imaging (f) and counting (g) of EGFP-positive autophagic vesicles in the cytosol of starvation-treated PC12 (Synwt) or PC12 (Synmt), with or without HMGB1 promoted. Each result was averaged for triple independent experiments. Statistical significance was presented as * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance
Fig. 4
Fig. 4
Western blot analysis of autophagy-associated markers in the PC12 (Synwt) or the PC12 (Synmt) cells, which were treated with HMGB1. a: Western blotting assay of LC3-I, LC3-II, Atg 7 and mTOR in the PC12 (Synwt) cells which were treated with 0, 0.2, 0.5 or 1 μg/mL HMGB1, under starvation for 24 hours; b: Ratio of LC3-II to LC3-I in the starvation-treated PC12 (Synwt) cells with HMGB1 treatment; c and d: Relative level of Atg 7 (c) and mTOR (d) levels to β-actin in the PC12 (Synwt) cells with HMGB1 treatment; e: Western blotting assay of LC3-I, LC3-II, Atg 7 and mTOR in the PC12 (Synmt) cells which were treated with 0, 0.2, 0.5 or 1 μg/mL HMGB1, under starvation for 24 hours; f: Ratio of LC3-II to LC3-I in the starvation-treated PC12 (Synmt) cells with HMGB1 treatment; g and h: Relative level of Atg 7 (g) and mTOR (h) levels to β-actin in the PC12 (Synmt) cells with HMGB1 treatment. Data was averaged for triple independent results, ns: no significance
Fig. 5
Fig. 5
Beclin1 upregulation reduces α-synuclein accumulation and ameliorates the α-synuclein-inhibited autophagy in PC12 (Synwt) and PC12 (Synmt) cells. a: Western blot analysis of Beclin1 and α-synuclein in the PC12 (Synwt) and PC12 (Synmt) cells which were infected with 1 multiplicity of infection (MOI) pLenti-Beclin1 (LV-Beclin1) or pLenti-Con (LV-Con) under starvation for 12 or 24 hours; b and c: Ratio of Beclin1 to β-actin in PC12 (Synwt) (b) and PC12 (Synmt) (c) cells which were infected with LV-Beclin1 or with LV-Con virus; d and e: Ratio of α-synuclein to β-actin in PC12 (Synwt) (b) and PC12 (Synmt) (c) cells which were infected with LV-Beclin1 or with LV-Con virus; f and g: Imaging (f) and counting (g) of EGFP-positive autophagic vesicles in the starvation-treated PC12 (Synwt) or PC12 (Synmt), which were infected with LV-Beclin1 or with LV-Con virus. Each result was averaged for triple independent experiments. Statistical significance was presented as * p < 0.05, ** p < 0.01, *** p < 0.001, ns: no significance

Similar articles

Cited by

References

    1. Irizarry MC, Growdon W, Gomez-Isla T, Newell K, George JM, Clayton DF, et al. Nigral and cortical Lewy bodies and dystrophic nigral neurites in Parkinson’s disease and cortical Lewy body disease contain alpha-synuclein immunoreactivity. J Neuropathol Exp Neurol. 1998;57(4):334–337. doi: 10.1097/00005072-199804000-00005. - DOI - PubMed
    1. Spillantini MG, Crowther RA, Jakes R, Hasegawa M, Goedert M. alpha-Synuclein in filamentous inclusions of Lewy bodies from Parkinson’s disease and dementia with lewy bodies. Proc Natl Acad Sci U S A. 1998;95(11):6469–6473. doi: 10.1073/pnas.95.11.6469. - DOI - PMC - PubMed
    1. Ebrahimi-Fakhari D, McLean PJ, Unni VK. Alpha-synuclein’s degradation in vivo: opening a new (cranial) window on the roles of degradation pathways in Parkinson disease. Autophagy. 2012;8(2):281–283. doi: 10.4161/auto.8.2.18938. - DOI - PMC - PubMed
    1. Ebrahimi-Fakhari D, Wahlster L, McLean PJ. Protein degradation pathways in Parkinson’s disease: curse or blessing. Acta Neuropathol. 2012;124(2):153–172. doi: 10.1007/s00401-012-1004-6. - DOI - PMC - PubMed
    1. Shacka JJ, Roth KA, Zhang J. The autophagy-lysosomal degradation pathway: role in neurodegenerative disease and therapy. Front Biosci. 2008;13:718–736. doi: 10.2741/2714. - DOI - PubMed

Publication types

MeSH terms